KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Receivables (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Change in Receivables data on record, last reported at $10.3 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 63.86% year-over-year to $10.3 million; the TTM value through Dec 2025 reached $120.6 million, down 25.87%, while the annual FY2025 figure was $120.6 million, 25.87% down from the prior year.
  • Change in Receivables reached $10.3 million in Q4 2025 per AMRX's latest filing, down from $77.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $129.0 million in Q2 2023 and bottomed at -$196.0 million in Q1 2023.
  • Average Change in Receivables over 5 years is $10.1 million, with a median of $23.3 million recorded in 2023.
  • Peak YoY movement for Change in Receivables: crashed 277.99% in 2021, then soared 455.83% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $34.5 million in 2021, then skyrocketed by 262.94% to $125.3 million in 2022, then tumbled by 161.66% to -$77.2 million in 2023, then surged by 137.04% to $28.6 million in 2024, then plummeted by 63.86% to $10.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $10.3 million in Q4 2025, $77.6 million in Q3 2025, and $53.8 million in Q2 2025.